Loading clinical trials...
Loading clinical trials...
ABLE: Phase II, Single Arm, Two-stage Study of Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer
Conditions
Interventions
Pembrolizumab
Abraxane
Locations
1
United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Start Date
February 8, 2018
Primary Completion Date
June 23, 2023
Completion Date
June 23, 2023
Last Updated
January 16, 2025
NCT05889195
NCT06857175
NCT04693377
NCT03317158
NCT06770582
NCT04895709
Lead Sponsor
University of Michigan Rogel Cancer Center
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions